These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24025362)

  • 1. Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer.
    Zhu W; Zhang H; Shi Y; Song M; Zhu B; Wei L
    Cancer Biol Ther; 2013 Nov; 14(11):1016-23. PubMed ID: 24025362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of Mcl-1 overcomes resistance of melanoma cells against TRAIL-armed oncolytic adenovirus by enhancement of apoptosis.
    Tolksdorf B; Zarif S; Eberle J; Hazini A; Dieringer B; Jönsson F; Kreppel F; Kurreck J; Fechner H
    J Mol Med (Berl); 2021 Sep; 99(9):1279-1291. PubMed ID: 34028599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer.
    Zhang R; Zhang X; Ma B; Xiao B; Huang F; Huang P; Ying C; Liu T; Wang Y
    Cancer Gene Ther; 2016 Jun; 23(6):168-77. PubMed ID: 27080225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus.
    Yang Y; Xu H; Huang W; Ding M; Xiao J; Yang D; Li H; Liu XY; Chu L
    J Cell Mol Med; 2015 May; 19(5):915-23. PubMed ID: 25683371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
    El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
    J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.
    Oh E; Hong J; Kwon OJ; Yun CO
    Sci Rep; 2018 Jan; 8(1):1420. PubMed ID: 29362367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer.
    Zhang Z; Huang Y; Newman K; Gu J; Zhang X; Wu H; Zhao M; Xianyu Z; Liu X
    Clin Cancer Res; 2009 Aug; 15(16):5154-60. PubMed ID: 19671855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis.
    Hu J; Wang H; Gu J; Liu X; Zhou X
    Acta Biochim Biophys Sin (Shanghai); 2018 Oct; 50(10):1018-1027. PubMed ID: 30137199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
    Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
    Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
    Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
    Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
    Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
    Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
    Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response.
    Jung BK; Oh E; Hong J; Lee Y; Park KD; Yun CO
    Biomaterials; 2017 Dec; 147():26-38. PubMed ID: 28923683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
    Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
    Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
    Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
    Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia.
    Wang Z; Liu W; Wang L; Gao P; Li Z; Wu J; Zhang H; Wu H; Kong W; Yu B; Yu X
    Signal Transduct Target Ther; 2020 Apr; 5(1):40. PubMed ID: 32327638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus.
    Zhang X; Komaki R; Wang L; Fang B; Chang JY
    Clin Cancer Res; 2008 May; 14(9):2813-23. PubMed ID: 18451249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer.
    Zhou W; Dai S; Zhu H; Song Z; Cai Y; Lee JB; Li Z; Hu X; Fang B; He C; Huang X
    Gene Ther; 2017 Apr; 24(4):199-207. PubMed ID: 28075429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest.
    Kang S; Kang D; Bakhtiar Ul Islam SM; Je S; Kim JH; Song JJ
    Cell Signal; 2015 Jun; 27(6):1214-24. PubMed ID: 25748050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.